BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang YG, Chen KX, Wu GL, Song FJ. An analysis: Colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol 2005; 11(6): 895-898 [PMID: 15682489 DOI: 10.3748/wjg.v11.i6.895]
URL: https://www.wjgnet.com/1007-9327/full/v11/i6/895.htm
Number Citing Articles
1
Jian‐Guo Chen, Jian Zhu, Donald Maxwell Parkin, Yong‐Hui Zhang, Jian‐Hua Lu, Yuan‐Rong Zhu, Tao‐Yang Chen. Trends in the incidence of cancer in Qidong, China, 1978–2002International Journal of Cancer 2006; 119(6): 1447 doi: 10.1002/ijc.21952
2
Jin Li, Jiliang Yin, Xiaodong Zhu, Yanfei Liu, Junning Cao, Fangfang Lu, Yunxia Zuo. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancerAnti-Cancer Drugs 2008; 19(7): 745 doi: 10.1097/CAD.0b013e3283067694
3
Rodney Hull, Flavia Zita Francies, Meryl Oyomno, Zodwa Dlamini. <p>Colorectal Cancer Genetics, Incidence and Risk Factors: In Search for Targeted Therapies</p>Cancer Management and Research 2020; : 9869 doi: 10.2147/CMAR.S251223
4
C. Xiaoyuan, C. Longbang, W. Jinghua, G. Xiaoxiang, G. Huaicheng, Z. Qun, S. Haizhu. Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancerIrish Journal of Medical Science 2010; 179(3): 327 doi: 10.1007/s11845-009-0448-8
5
C-H Jin, A-H Wang, J-M Chen, R-X Li, X-M Liu, G-P Wang, L-Q Xing. Observation of Curative Efficacy and Prognosis following Combination Chemotherapy with Celecoxib in the Treatment of Advanced Colorectal CancerJournal of International Medical Research 2011; 39(6): 2129 doi: 10.1177/147323001103900609